Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Kosan BioSciences -- KOSN -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (928)	5/29/2008 1:08:40 PM
From: rkrw	Respond to of 933

I think the royalty is single digit. Been trying to find out but haven't got a good answer. I dont think DNA would munch them to save such a small royalty, considering they never took Idec or OSIP for 25-30%. Also not sure CRIS has any ongoing effort to find new hedgehogs in cancer other than through dna. Cris focus seems to be on these hdac combinations and their claim they have some sort of highly synergistic effect but its probably smart to be skeptical without clinical proof... I think a lot of small biotechs are on the block, most probably won't happen, but a few will. Kosan, amazing deal. Iomi got a great deal the other day as well. I'm assuming Bristol is a lot more interested in the epothilone than hsp90 but maybe I'm wrong.